FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2801916733> ?p ?o ?g. }

• W2801916733 abstract "Background and objectives: Newborns with perinatal risk factors and abnormal general motor quality assessment are at high risk of developing cerebral palsy. The treatment is earlier, the prognosis is better. This trial will investigate whether, combined with conventional early interventional therapy, the use of mouse nerve growth factor in high-risk infants can improve their motor and cognitive abilities. Design: This is a prospective, single-center, randomized, parallel, controlled, clinical trial. Methods: This trial will be conducted in the Department of Developmental Behavioral Pediatrics, the First Hospital of Jilin University, China. One hundred high-risk infants meeting the inclusion criteria will be recruited and randomized into control and treatment groups. Only participants in the treatment group will undergo the early treatment of mouse nerve growth factor via gluteus maximus injections, 20 μg per dose, once a day, 10 consecutive days per month. The treatment will last for 6 months. Both groups will receive standard early intervention therapies. Outcome measures: The primary outcome measure is the incidence of the developmental disorders cerebral palsy and non-cerebral palsy at the actual age or corrected age of 12 months. The secondary outcome measures are Gesell Developmental Schedule scores at the actual age or corrected age of 12 months, Gross Motor Function Measure score at 6 and 12 months of treatment, and adverse events during the trial. Discussion: If treatment with mouse nerve growth factor is found to be safe and effective for the high-risk infants, new options for the early-stage clinical treatment for such infants may be developed. Ethics and dissemination: This trial has been approved by the Ethics Committee of First Hospital of Jilin University of China [approval number: 2017 (2017-290)]. This trial was designed in August 2017. Ethics approval was done in October 2017. This trial was registered in November 2017. The recruitment of subjects began in December 2017. Data analysis will be finished in December 2021. The results of the trial will be reported in a scientific conference or disseminated in a peer-reviewed journal. Anonymized trial data will be available indefinitely at www.figshare.com . Trial registration: This trial has been registered in the Chinese Clinical Trial Registry (registration number: ChiCTR-IPR-17012774). Protocol version (2.0)." @default.
• W2801916733 created "2018-05-17" @default.
• W2801916733 creator A5030641434 @default.
• W2801916733 creator A5037836109 @default.
• W2801916733 creator A5057990267 @default.
• W2801916733 creator A5079782478 @default.
• W2801916733 creator A5087704707 @default.
• W2801916733 date "2018-01-01" @default.
• W2801916733 modified "2023-09-27" @default.
• W2801916733 title "Does early injection of mouse nerve growth factor affect motor and cognitive abilities in high-risk infants? study protocol for a randomized parallel-controlled trial" @default.
• W2801916733 doi "https://doi.org/10.4103/2542-3932.232080" @default.
• W2801916733 hasPublicationYear "2018" @default.
• W2801916733 type Work @default.
• W2801916733 sameAs 2801916733 @default.
• W2801916733 citedByCount "1" @default.
• W2801916733 countsByYear W28019167332019 @default.
• W2801916733 crossrefType "journal-article" @default.
• W2801916733 hasAuthorship W2801916733A5030641434 @default.
• W2801916733 hasAuthorship W2801916733A5037836109 @default.
• W2801916733 hasAuthorship W2801916733A5057990267 @default.
• W2801916733 hasAuthorship W2801916733A5079782478 @default.
• W2801916733 hasAuthorship W2801916733A5087704707 @default.
• W2801916733 hasConcept C126322002 @default.
• W2801916733 hasConcept C141071460 @default.
• W2801916733 hasConcept C168563851 @default.
• W2801916733 hasConcept C1862650 @default.
• W2801916733 hasConcept C187212893 @default.
• W2801916733 hasConcept C2779421357 @default.
• W2801916733 hasConcept C50440223 @default.
• W2801916733 hasConcept C535046627 @default.
• W2801916733 hasConcept C71924100 @default.
• W2801916733 hasConceptScore W2801916733C126322002 @default.
• W2801916733 hasConceptScore W2801916733C141071460 @default.
• W2801916733 hasConceptScore W2801916733C168563851 @default.
• W2801916733 hasConceptScore W2801916733C1862650 @default.
• W2801916733 hasConceptScore W2801916733C187212893 @default.
• W2801916733 hasConceptScore W2801916733C2779421357 @default.
• W2801916733 hasConceptScore W2801916733C50440223 @default.
• W2801916733 hasConceptScore W2801916733C535046627 @default.
• W2801916733 hasConceptScore W2801916733C71924100 @default.
• W2801916733 hasLocation W28019167331 @default.
• W2801916733 hasOpenAccess W2801916733 @default.
• W2801916733 hasPrimaryLocation W28019167331 @default.
• W2801916733 hasRelatedWork W1978512649 @default.
• W2801916733 hasRelatedWork W1988677320 @default.
• W2801916733 hasRelatedWork W1999014734 @default.
• W2801916733 hasRelatedWork W2041041219 @default.
• W2801916733 hasRelatedWork W2104130159 @default.
• W2801916733 hasRelatedWork W2106820763 @default.
• W2801916733 hasRelatedWork W2114138841 @default.
• W2801916733 hasRelatedWork W2123309226 @default.
• W2801916733 hasRelatedWork W2332711688 @default.
• W2801916733 hasRelatedWork W2341740619 @default.
• W2801916733 hasRelatedWork W2588127758 @default.
• W2801916733 hasRelatedWork W2738015946 @default.
• W2801916733 hasRelatedWork W2784099315 @default.
• W2801916733 hasRelatedWork W2792752520 @default.
• W2801916733 hasRelatedWork W2901613145 @default.
• W2801916733 hasRelatedWork W2903943289 @default.
• W2801916733 hasRelatedWork W2915398474 @default.
• W2801916733 hasRelatedWork W2935033070 @default.
• W2801916733 hasRelatedWork W3180182607 @default.
• W2801916733 hasRelatedWork W3203596693 @default.
• W2801916733 isParatext "false" @default.
• W2801916733 isRetracted "false" @default.
• W2801916733 magId "2801916733" @default.
• W2801916733 workType "article" @default.